GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Interest Coverage

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Interest Coverage : No Debt (1) (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. InVivo Therapeutics Holdings's Operating Income for the three months ended in Sep. 2023 was $-2.83 Mil. InVivo Therapeutics Holdings's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. InVivo Therapeutics Holdings has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. InVivo Therapeutics Holdings Corp has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for InVivo Therapeutics Holdings's Interest Coverage or its related term are showing as below:


NVIVQ's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 114.62
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


InVivo Therapeutics Holdings Interest Coverage Historical Data

The historical data trend for InVivo Therapeutics Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InVivo Therapeutics Holdings Interest Coverage Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt N/A N/A N/A N/A

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A No Debt

Competitive Comparison of InVivo Therapeutics Holdings's Interest Coverage

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Interest Coverage falls into.



InVivo Therapeutics Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InVivo Therapeutics Holdings's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, InVivo Therapeutics Holdings's Interest Expense was $0.00 Mil. Its Operating Income was $-10.65 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.55 Mil.

GuruFocus does not calculate InVivo Therapeutics Holdings's interest coverage with the available data.

InVivo Therapeutics Holdings's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, InVivo Therapeutics Holdings's Interest Expense was $0.00 Mil. Its Operating Income was $-2.83 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

InVivo Therapeutics Holdings had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


InVivo Therapeutics Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070